logo
College student, 22, brushed off 2 common symptoms as a sinus infection before being diagnosed with CANCER

College student, 22, brushed off 2 common symptoms as a sinus infection before being diagnosed with CANCER

Daily Mail​29-04-2025
A Texas college student has revealed how a headache and pressure in her nose led her to discover she was suffering from an acute form of blood cancer.
In September 2024, Breeze Hunter, 22, a student at Texas A&M University, felt like she was having a 'rubber band' pulling at her head and was rapidly losing weight.
However, she kept dismissing her changing body and constant pain as a persistent sinus infection, something she was prone to.
The young student recalled: 'I had a lot of fluid in my ears, which was causing the headaches. I went to a clinic a few times and they pretty much said it was a sinus infection.'
But a month later, she decided to visit the doctor's office on her campus after finding herself too weak to walk up a flight of stairs or even go to classes - where she underwent a blood test.
Realizing that Hunter was severely anemic - where the body lacks enough healthy red blood cells - doctors at the clinic urged her to go to an emergency room.
She then tried going to an ER close to her campus but since they were full, Hunter decided to visit The University of Texas Medical Branch Hospital in her hometown League City, Texas.
After multiple blood tests, Hunter and her family were finally told that she was suffering from high risk acute myeloid leukemia, an aggressive blood cancer and was admitted to MD Anderson Cancer Center, Houston.
She told TODAY.com: 'I told them that the headaches are still here. I'm very weak and had fatigue. They recommended doing a blood test.'
'I had many people coming in and saying, 'It's looking like a sign of leukemia, but we'll keep testing because it could be a bunch of other things'.
'I freaked out. I had no idea what leukemia was. I was like am I going to survive this? Or is it treatable?'
Acute myeloid leukemia affects the myeloid cells in the bone marrow which are responsible for maturing into red and white blood cells in the bloodstream.
Once turned cancerous, these cells move from the bone marrow into the blood and spread the disease to other parts of the body, including the lymph nodes, liver, spleen, brain and spinal cord.
When it affects the brain and spinal cord, it can cause symptoms like headaches and weakness in the body.
Unlike other cancers, there are no numbered stages of AML and it can progress in rapid speeds.
Some symptoms of AML include fatigue, feeling cold, dizziness, pale skin, shortness of breath, easy bruising and bleeding with no clear cause.
The exact causes are unclear, however, smoking, being overweight, radiation exposure and previous chemotherapy can increase risks of developing AML.
But many patients, like Breeze Hunter, don't fall into any of those categories.
In 2024, over 20,00 Americans were diagnosed with AML and about 11,200 people died from the condition.
Possible treatments often include chemotherapy, targeted therapy and at times stem cell transplantation (a medical procedure that replaces diseased or damaged blood-forming stem cells with healthy ones from a donor).
Within days of being diagnosed, Hunter underwent a bone marrow aspiration (a sample of the liquid part of bone marrow taken for testing) and a spinal tap (a sample of cerebrospinal fluid taken from the lower part of the spine).
The doctors at the MD Anderson Cancer Center also kept her in the hospital and placed her seven days of chemotherapy infusions along with an experimental cancer-fighting pill, which was part of a clinical trial.
Much to their surprise, doctors tested Hunter's bone marrow after 21 days of starting chemotherapy to see if the treatment worked and saw improvement.
She was then placed on a second seven-day round of the treatment and showed significant improvement.
'I was supposed to get at least six rounds,' Hunter said. 'The chemo worked so well I only had to do two.'
According to her now-viral TikTok page, the college student was on a six-month chemotherapy plan that ended earlier this year.
After undergoing 11 rounds of radiation to kill any possible lingering cancer cells in her brain and spine plus an new intense round of chemotherapy, she received a stem cell transplant from her 21-year-old brother, Roy.
A stem cell transplant, also known as a bone marrow transplant, replaces damaged or diseased bone marrow with healthy stem cells that can develop into different types of blood cells.
It is done to treat various conditions, including certain cancers, blood disorders, and autoimmune diseases.
'I got a radiation/chemo burn all over my body, which was very very painful and I was pretty much burnt all over,' she said. The chemotherapy regimen 'was harder than the leukemia one.'
Following the transplant, she has remained in the hospital for to make sure everything went well and protect her from potential infection from her weakened immune system.
'Probably towards the end I was over it. I was like, 'I can't do this. This is too much,' Hunter recalled. 'It was very hard at times but God's watching me. So, I knew I was going to be OK.'
Since the end of her intense treatment, Hunter is now in remission and claims to feel better as well as stronger and intends to walk in her college graduation soon.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Summer Covid cases are rising across the U.S. — Is it time for a vaccine?
Summer Covid cases are rising across the U.S. — Is it time for a vaccine?

NBC News

time13 hours ago

  • NBC News

Summer Covid cases are rising across the U.S. — Is it time for a vaccine?

As Covid cases begin to rise this summer, many may be wondering: What are my risks, and is it time to get another vaccine? As of July 15, Covid cases were growing or likely growing in 27 states including Texas, Illinois, Kentucky, Virginia and Ohio, according to the Centers for Disease Control and Prevention. Rates of positive Covid tests have also been increasing in recent weeks, the CDC says, specifically in the southern region of the country. N.B.1.8.1 is the current dominant variant in the United States, accounting for 43% of all new Covid cases, according to the CDC. It's an offshoot of the XVD.1.5.1 strain, a descendant of the omicron variant. N.B.1.8.1 was responsible for a surge in hospitalizations in China earlier this year. It's been nicknamed 'razor blade throat,' as there have been anecdotal reports of some people getting painful sore throats, said Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center in Nashville, Tennessee. Schaffner noted, however, that sore throats have been a common symptom of Covid since it first began spreading. 'I doubt the clinical spectrum of Covid has changed substantially,' Schaffner said. Do I need a Covid booster? When will the new vaccines be available? The uptick in cases comes as many Americans have likely gone a year or longer without a Covid shot. In May, the Food and Drug Administration asked drugmakers to update their Covid vaccines to target the LP.8.1 strain, a descendent of JN.1, which began spreading widely in 2023 and is another offshoot of omicron. LP.8.1 currently accounts for 31% of all new cases, per the CDC. The new shots won't be available until the fall, and are expected to be approved only for adults 65 and up and kids and adults with at least one medical condition that puts them at risk of severe illness. Healthy kids and adults who want a shot may have to find an older version or pay out of pocket. A single dose can cost as much as $140. Experts say, however, that population immunity — whether from vaccination, prior infection or both — may shield much of the public for now. 'While we don't have a lot of high level of immunity in the population right now, because it's been so long, we may have enough low level immunity to just make it a little bit harder for that virus to transmit easily from person to person,' said Andy Pekosz, an infectious disease researcher at Johns Hopkins University. Indeed, weekly hospitalization rates have remained low, suggesting that the new variant may not be leading to severe illness. The number of cases are still drastically lower than those this time last year, when the test positivity rate peaked in August at 17.9%. The 2025 season has yet to scrape 5%. Pekosz said it isn't unusual for cases to rise during the summer time, when people are likely to crowd indoors to escape the heat. However, he believes that if there is a summer surge of cases, it will be a small one. 'The variants have been around for a while and haven't caused any major surges up until date,' Pekosz said. 'So again, I'm hopeful that if we see a surge, it'll be a low level surge compared to previous years.' Dr. Ofer Levy, director of the precision vaccines program at Boston Children's Hospital, who has advised the FDA, said people who are at high risk of severe illness still may want to consider getting a Covid shot, if they can find one. High risk groups include: Older adults People with weakened immune systems Pregnant women Those with underlying health conditions, such as asthma and heart disease Getting a shot is especially important, Levy said, for those who haven't had one in over a year and whose immunity has likely waned. 'If you're in a high risk group and you're in a state where cases are rising, you may want to just get the first available appointment and get a shot to protect yourself,' he said. People at high risk can then consider getting an additional Covid shot when the updated vaccines are distributed in the fall, he said. Covid has two waves a year Schaffner, of Vanderbilt, said people in the high risk groups may also want to consider wearing a mask during indoor activities, such as the movies. Healthy adults and children may be able to wait longer before getting another shot, Levy added. 'If you're in a lower risk group, that's where things get fuzzy,' he said. 'I mean if you want a vaccine and your health care provider concurs and you can get it.' Dr. Michael Phillips, an infectious disease doctor at NYU Langone, said that he sees mostly immunocompromised and older adults test positive for the virus. For those who haven't gotten a Covid shot in years, Phillips said he doesn't think they should worry just yet. 'If you're younger, otherwise healthy, I think you're OK,' Phillips said. 'If you have underlying pulmonary disease, you know, if you're an older age group, now that's a time when you should be really talking to a doctor and saying, 'Gosh, should I be getting a booster for Covid?'' He said that the amount of positive Covid tests NYU Langone has seen has decreased 40% since February. Fatima Amaeka, a senior analyst at the Center for Outbreak Response Innovation at Johns Hopkins, said she expects the current wave to peak around September. Schaffner said to expect another wave in the late fall and winter. '[Covid] has two increases each year,' he said. 'Everyone is familiar with the winter increase that goes along with flu and RSV.'

AstraZeneca unveils plans for £37bn investment in US amid tariff threats
AstraZeneca unveils plans for £37bn investment in US amid tariff threats

North Wales Chronicle

time2 days ago

  • North Wales Chronicle

AstraZeneca unveils plans for £37bn investment in US amid tariff threats

The Cambridge-headquartered firm said the investment will fund a new 'state-of-the-art' manufacturing facility in Virginia – set to be its largest single manufacturing investment in the world. It will also expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas. The announcement marks the latest by a global pharmaceutical giant to expand its footprint in the US as Mr Trump has threatened to impose tariffs of up to 20% on drug imports in an effort to increase manufacturing in America and drive down costs for Americans. AstraZeneca said the mammoth investment will create tens of thousands of jobs across the US, 'powering growth and delivering next-generation medicines for patients in America and worldwide'. The Anglo-Swedish group, which is listed on the FTSE 100, said the investment will also help it towards the group's target of reaching 80 billion US dollars (£59.4 billion) in revenues by 2030. Half of this is expected to come from the US, it added. Pascal Soriot, chief executive of AstraZeneca, said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.' Despite being headquartered in the UK, America is AstraZeneca's largest market, where it employs more than 18,000 staff and makes 42% of total group sales. It already has 19 R&D, manufacturing and commercial sites across the country. The new factory planned for Virginia will produce drug substances for the company's weight management and metabolic portfolio, it said. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. 'President Trump and our nation's new tariff policies are focused on ending this structural weakness. 'We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores.'

AstraZeneca unveils plans for £37bn investment in US amid tariff threats
AstraZeneca unveils plans for £37bn investment in US amid tariff threats

Leader Live

time2 days ago

  • Leader Live

AstraZeneca unveils plans for £37bn investment in US amid tariff threats

The Cambridge-headquartered firm said the investment will fund a new 'state-of-the-art' manufacturing facility in Virginia – set to be its largest single manufacturing investment in the world. It will also expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas. The announcement marks the latest by a global pharmaceutical giant to expand its footprint in the US as Mr Trump has threatened to impose tariffs of up to 20% on drug imports in an effort to increase manufacturing in America and drive down costs for Americans. AstraZeneca said the mammoth investment will create tens of thousands of jobs across the US, 'powering growth and delivering next-generation medicines for patients in America and worldwide'. The Anglo-Swedish group, which is listed on the FTSE 100, said the investment will also help it towards the group's target of reaching 80 billion US dollars (£59.4 billion) in revenues by 2030. Half of this is expected to come from the US, it added. Pascal Soriot, chief executive of AstraZeneca, said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.' Despite being headquartered in the UK, America is AstraZeneca's largest market, where it employs more than 18,000 staff and makes 42% of total group sales. It already has 19 R&D, manufacturing and commercial sites across the country. The new factory planned for Virginia will produce drug substances for the company's weight management and metabolic portfolio, it said. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. 'President Trump and our nation's new tariff policies are focused on ending this structural weakness. 'We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store